Hobbs, Brian D
Morrow, Jarrett D
Wang, Xu-Wen
Liu, Yang-Yu
DeMeo, Dawn L
Hersh, Craig P
Celli, Bartolome R
Bueno, Raphael
Criner, Gerard J
Silverman, Edwin K
Cho, Michael H
Funding for this research was provided by:
National Heart, Lung, and Blood Institute (K08 HL136928, K25 HL136846, P01 HL132825, R01 HL157879, R01 HL152728, U01 HL089856)
National Institute of Allergy and Infectious Diseases (R01 AI141529)
National Human Genome Research Institute (R01 HG011393)
National Cancer Institute (R01 CA120528)
National Institute of Biomedical Imaging and Bioengineering (R01 EB025964)
Article History
Received: 31 May 2022
Accepted: 15 March 2023
First Online: 11 April 2023
Declarations
:
: Lung tissue samples were collected at one of three clinical centers including Brigham and Women’s Hospital (Boston, MA), St. Elizabeth’s Medical Center (Brighton, MA), and Temple University Hospital (Philadelphia, PA). Subjects provided written informed consent and Institutional Review Board approval was obtained at all three clinical centers. All methods and analyses were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: JDM, XWW, YYL, and GJC have no potential conflicts of interest to disclose. BDH receives grant support from Bayer. DLD has received support from Bayer and honoraria from Novartis. CPH reports grant support from Bayer, Boehringer-Ingelheim, Novartis, and Vertex and consulting fees from AstraZeneca and Takeda. BRC reports grant support from CHIESI Farmaceutici; speaking or consulting fees from GSK, AstraZeneca, Menarini, Sanofi Aventis, and Axios; membership on an advisory board with Vertex; and payment or honoraria from Regeneron. RB has received grants/research support from Verastem, Genentech, Roche, Myriad Genetics, Novartis, Siemens, Gritstone, HTG Molecular Diagnostics, Epizyme, MedGenome, Celsius, Merck, Bicycle Therapeutics, Bayer, Intuitive Surgical, and Northpond. RB has accepted consulting fees from Regeneron. RB has patents licensed to the Brigham and Equity in Navigation Sciences. In the past three years, EKS has received grants support from GSK and Bayer. MHC has received grant funding from GSK and Bayer, and speaking or consulting fees from AstraZeneca, Illumina, and Genentech.